Safety of intravitreal injection of bevacizumab in rabbit eyes.
OBJECTIVE
To evaluate the safety of intravitreal injection of bevacizumab in rabbits using electrophysiological testing and histopathologic analysis.


METHODS
New Zealand albino rabbits were injected in one eye with control antibody (n = 2), 0.05 mL of bevacizumab (n = 3), or 0.2 mL of bevacizumab (n = 3). Electroretinograms were obtained 1 week and 4 weeks after injection. Histologic analysis was performed after completion of the electroretinographic studies.


RESULTS
No statistical differences were seen in scotopic and photopic a- and b-wave amplitudes between untreated control and bevacizumab-injected eyes. No histopathologic differences were identified between untreated control and bevacizumab-injected eyes.


CONCLUSIONS
Our study did not find evidence of retinal toxicity from a single intravitreal injection of bevacizumab in rabbits.
Feiner
Leonard
L
Department of Ophthalmology and Visual Sciences/Campus Box 8096, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
Barr
Emily E
EE
Shui
Ying-Bo
YB
Holekamp
Nancy M
NM
Brantley
Milam A
MA
D020533:Angiogenesis Inhibitors / Q000633:toxicity*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003623:Dark Adaptation; D004596:Electroretinography; D007267:Injections; D010775:Photic Stimulation; D011817:Rabbits; D012160:Retina / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab